Valneva SE (VALN) Non-Current Debt (2020 - 2026)
Valneva SE's (VALN) quarterly Non-Current Debt came in at $192.1 million in Q1 2026, up 13.08% year-on-year from $169.9 million in Q1 2025, and up 2.32% quarter-over-quarter from $187.7 million in Q4 2025.
Valneva SE (VALN) Non-Current Debt (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Non-Current Debt across 7 years of filings, most recently posting $192.1 million for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $192.1 million, up 13.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $192.1 million (up 13.08% YoY), and the FY2025 annual result was $187.7 million, up 5.49% from the prior year.
- Non-Current Debt came in at $192.1 million for Q1 2026 at Valneva SE, up from $187.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $192.1 million in Q1 2026 to a low of $53.9 million in Q1 2022.
- The 5-year median for Non-Current Debt is $138.5 million (2025), against an average of $132.1 million.
- Across the five-year window, Non-Current Debt surged 113.94% in 2024 and fell 24.3% in 2025, its largest moves.
- Valneva SE's Non-Current Debt stood at $89.0 million in 2022, then surged by 60.52% to $142.9 million in 2023, then gained by 24.57% to $177.9 million in 2024, then rose by 5.49% to $187.7 million in 2025, then increased by 2.32% to $192.1 million in 2026.
- The last three Non-Current Debt figures came in at $192.1 million (Q1 2026), $187.7 million (Q4 2025), and $127.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 192.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.07 Mn |
| Mar 31, 2026 | 192.07 Mn |
| Dec 31, 2025 | 187.71 Mn |
| Dec 31, 2025 | 187.71 Mn |
| Sep 30, 2025 | 127.30 Mn |
| Sep 30, 2025 | 127.30 Mn |
| Jun 30, 2025 | 138.51 Mn |
| Jun 30, 2025 | 138.51 Mn |
| Mar 31, 2025 | 169.86 Mn |
| Mar 31, 2025 | 169.86 Mn |
| Dec 31, 2024 | 177.94 Mn |
| Dec 31, 2024 | 177.94 Mn |
| Sep 30, 2024 | 168.17 Mn |
| Sep 30, 2024 | 168.17 Mn |
| Jun 30, 2024 | 172.89 Mn |
| Jun 30, 2024 | 172.89 Mn |
| Mar 31, 2024 | 172.77 Mn |
| Mar 31, 2024 | 172.77 Mn |
| Dec 31, 2023 | 142.85 Mn |
| Dec 31, 2023 | 142.85 Mn |